Drug intelligence / Profile preview

BCT-305

Development stage: Preclinical
Lead developer: ITL Pharma
Modality: Small Molecules

Overview

BCT-305 is an investigational pharmaceutical candidate reported as a small-molecule thyroid hormone receptor agonist program for hypothyroidism. Publicly available pipeline references are sparse, but the asset has been described as a dual thyroid hormone receptor alpha and thyroid hormone receptor beta agonist being developed by Itl Pharma, with preclinical development activity reported for hypothyroidism. Because source detail is limited and largely confined to pipeline aggregation databases rather than primary company disclosures, the exact molecular identity, formulation, route, and clinical development history remain insufficiently characterized in the public domain.

Other names: BCT-305/BCT-306

Targets

THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on BCT-305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCT-305.

Explore the full profile